Replies to post #133365 on Biotech Values

[BTH]

I really think companies should develop their drugs in a way that would allow them to by-pass a lengthy Phase 3 trial, similar to what Ariad is doing with Ponatinib. Clearly Pona is a unique example. Problem is, a lot of development companies are borderline scams that are just ATM machines for Executives and Board Members so their Phase 1 trials are complete nonsense, instead of a true Phase 1/2.

I read a really good abstract not too long ago re: avoiding Phase 3 trials by designing better focused trials based on personaized medicine. ...which would hopefully speed up the nonsense of taking 15 years to get a drug from lab to marketing approval.